Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)

John Cannon, Colm McCabe, Joanna Pepke-Zaba, Karen Sheares
European Respiratory Journal 2012 40: P948; DOI:
John Cannon
1Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colm McCabe
1Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Pepke-Zaba
1Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Sheares
1Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure2
    • Download figure
    • Open in new tab
    • Download powerpoint

Tables

  • Figures
  •  Responders n=8Non-responders n=5p value
    Age y60.858.80.71
    Gender M:F4:43:2 
    Follow up m54.817.40.02
    Sarcoid stage III/IV3:51:40.66
    NYHA Functional Class7:15:10.81
    mPAP52.645.40.11
    CI1.851.640.20
    PVR dyn10016480.046
    FVC %61660.61
    KCO%50530.79
    6MWDδm+78-520.004
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
John Cannon, Colm McCabe, Joanna Pepke-Zaba, Karen Sheares
European Respiratory Journal Sep 2012, 40 (Suppl 56) P948;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
John Cannon, Colm McCabe, Joanna Pepke-Zaba, Karen Sheares
European Respiratory Journal Sep 2012, 40 (Suppl 56) P948;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction
  • LSC Abstract – Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension
  • CD163 is expressed and modulated in human pulmonary artery smooth muscle cells: Implications for pulmonary artery hypertension
Show more 4.3 Pulmonary Circulation and Pulmonary Vascular Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society